SMMT — Summit Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1599298 ·
Last close
$10.67
Market Cap
$8.53B
52W High
$29.23
52W Low
$10.53
ADV30
5,990,067
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -214,611,000 | -208,385,000 | 692,850,000 | 150,811,000 | 128,167,000 |
| Jun 2026 | 0 | — | -220,496,000 | -215,700,000 | 752,185,000 | 419,365,000 | 122,202,000 |
| Mar 2026 | 0 | — | -195,212,000 | -189,424,000 | 647,856,000 | 106,515,000 | 101,924,000 |
| Dec 2025 | 0 | — | -224,875,000 | -219,172,000 | 751,182,000 | 225,266,000 | 92,322,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-525,167,000
Investing CF
$-466,663,000
Financing CF
$904,128,000
CapEx
$-1,714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,907,668,000
Inventory
—
Receivables
—
ST Investments
$478,976,000
EBIT TTM
$-849,441,000
Pretax Income TTM
$-832,631,000
Interest Exp TTM
$0
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,094,374,000 | -1,079,586,000 | 751,182,000 | 92,322,000 | 658,860,000 | -322,930,000 |
| Dec 2024 | 0 | -210,977,000 | -221,315,000 | 435,560,000 | 46,812,000 | 388,748,000 | -142,106,000 |
| Dec 2023 | 0 | -88,735,000 | -614,928,000 | 202,949,000 | 125,257,000 | 77,692,000 | -76,760,000 |
| Dec 2022 | 705,000 | -63,621,000 | -78,782,000 | 664,168,000 | 537,514,000 | 126,654,000 | -41,582,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-856,089,000
OpCashFlow TTM
—
Assets (Latest)
$752,185,000
Forward EPS
$-1.06
Max Pain — expiry 2027-01-15
max pain strike: $19.00 · spot: $10.50 · call oi: 0 · put oi: 2,877
Expected Move to 2027-01-15:
±$4.85
(46.19%) —
implied range
$5.65 –
$15.35
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRAX | Praxis Precision Medicines, Inc. | $8.53B | $305.06 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.91B | $93.81 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.07B | $124.67 | — |
| TGTX | TG THERAPEUTICS, INC. | $9.48B | $62.71 | — |
News headlines (Yahoo Finance, 1h cache)
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
2026-11-18 14:21 · Yahoo
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer
2026-11-18 11:00 · Yahoo
Summit Therapeutics (SMMT) Is Losing Wall Street’s Confidence
2026-11-18 06:58 · Yahoo
Summit Therapeutics (SMMT) Stock Sees Modest Fair Value Cut As Analysts Weigh Trial Risks
2026-11-17 11:14 · Yahoo
Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback
2026-11-17 02:20 · Yahoo
Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug
2026-11-16 21:27 · Yahoo
2 Cancer-Drug Developers Seeing Unusual Options Volume
2026-11-16 18:01 · Yahoo
Summit Therapeutics (SMMT) Faces An FDA Reset, Is The Downside Already Priced In?
2026-11-16 17:14 · Yahoo
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
2026-11-16 17:14 · Yahoo
AstraZeneca Bet $2 Billion on Summit’s Cancer Drug. The FDA Just Said Not Yet.
2026-11-16 16:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.